Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Idarucizumab

Hazard - P - B - T - Risk Exempt

Information

Assessment report

Assessment report for Praxbind (idarucizumab), 24 September 2015, EMA/713107/2015.

"The Fab idarucizumab is a protein which is unlikely to result in significant risk to the environment. This was agreed by the CHMP."

Fass environmental information

Fass environmental information for Praxbind from Boehringer Ingelheim (downloaded 2019-09-04).

Risk

The use of amino acids, proteins and peptides is not expected to have any environmental impact.

Detailed information

According to the European Medicines Agency guideline on environmental risk assessments for pharmaceuticals (EMA/CHMP/SWP/4447/00),vitamins, electrolytes, amino acids, peptides, proteins, carbohydrates, lipids proteins, vaccines and herbal medicinal products are exempted because they are unlikely to result in significant risk to the environment.

Author: Health and Medical Care Administration, Region Stockholm